• In 2023, two new interventions to protect infants from respiratory syncytial virus (RSV) became available in the United States:

  • RSVpreF vaccine for pregnant individuals to be administered at 32-36 weeks gestation - RSVpreF, which protects infants through maternal vaccination, demonstrated an efficacy of 82% against severe RSV disease in the first few months of life.

  • Nirsevimab, a monoclonal antibody for infants under 8 months - Nirsevimab was approved in the US for use in infants and showed high efficacy in clinical trials, with an 81% reduction in RSV-related hospitalizations.

• A study was conducted at Kaiser Permanente Northern California to assess the effect on uptake of RSVpreF and nirsevimab of various sociodemographic factors associated.

• Objective: To estimate the uptake of protective measures against RSV amongst mothers and infants born in at KPNC.

• Methods: Data from electronic medical records of infants born at KPNC to mothers aged 15 years to 49 years October 17, 2023 and March 31, 2024 was reviewed.

• Results: The results revealed that out of 17,251 infants, 77.5% received protection through either RSVpreF or Nirsevimab. 33.9% were exposed solely to RSVpreF, while 40.9% received only nirsevimab. A small percentage (2.7%) received both interventions. Notably, younger mothers were less likely to have received RSVpreF but more likely to have their infants receive nirsevimab.

• Conclusion: Nearly 80% of infants born during the RSV season received protection against the virus, with disparities in vaccination rates among different demographic groups.

Click here to read more.